According to a study, 1 in 5 dialysis facilities might face financial losses if calcimimetics are included in the payment bundle, and providers may feel pressured to reduce calcimimetic use. The ...
Study findings suggest serum phosphate is a negative modulator of calcium receptor activation. Hyperphosphatemia can diminish the ability of calcimimetics to activate the calcium-sensing receptor, but ...
Calcimimetics suppress the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the ...
For example, oral calcimimetics, a form of treatment for ESRD-related secondary hyperparathyroidism (SHPT), are currently outside of the bundle but slated for inclusion in the future. Bundled Payments ...
Please provide your email address to receive an email when new articles are posted on . CMS has proposed a $16.26 increase to the Medicare composite rate for dialysis treatments in 2021 to help cover ...
Considerable advances have been made in the understanding of the pathogenesis and treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD). These include the discovery that ...
The in-depth research report on Calcimimetics Market added to its huge repository by DBMR provides imprehensive and all aspects of market research. The market insights of this market report helps with ...
A recent research report on Global Calcimimetics Market Industry Analysis and Opportunity Assessment 2021-2028 by Data Bridge Market Research comprises of productive information of the market. The ...
Secondary Hyperparathyroidism in Nondialyzed Stage 3 and 4 CKD Patients Concomitant use of cinacalcet and drugs that alter the activity of cinacalcet-metabolizing enzymes might necessitate alteration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results